These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14561942)

  • 41. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 42. [Heart failure: a neurohormonal disorder?].
    Forleo C; De Tommasi E; Pitzalis MV; Rizzon P
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):291-4. PubMed ID: 12497923
    [No Abstract]   [Full Text] [Related]  

  • 43. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure.
    Bauersachs J; Fraccarollo D; Galuppo P; Widder J; Ertl G
    Cardiovasc Res; 2000 Jul; 47(1):142-9. PubMed ID: 10869540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
    Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
    J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cardiac failure and neurohumoral factors].
    Kinoshita M
    Nihon Naika Gakkai Zasshi; 2000 Sep; 89(9):1750-64. PubMed ID: 11051646
    [No Abstract]   [Full Text] [Related]  

  • 46. Endothelin in cardiovascular disease: from atherosclerosis to heart failure.
    Best PJ; Lerman A
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S61-63. PubMed ID: 10976784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endothelins.
    Lüscher TF; Lerman A
    Cardiovasc Res; 1998 Sep; 39(3):529. PubMed ID: 9861292
    [No Abstract]   [Full Text] [Related]  

  • 48. A functional role for endogenous atrial natriuretic peptide in the maintenance of body fluid balance in heart failure.
    Kinoshita M; Wada A
    Intern Med; 1998 Feb; 37(2):225-8. PubMed ID: 9550619
    [No Abstract]   [Full Text] [Related]  

  • 49. [Neurohumoral regulation in heart failure].
    Riegger GA; Muders F; Luchner A
    Z Kardiol; 1996; 85 Suppl 6():205-10. PubMed ID: 9064967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endothelin in congestive heart failure.
    Love MP; McMurray JJ
    Basic Res Cardiol; 1996; 91 Suppl 1():21-9. PubMed ID: 8896740
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highlights on endothelins: a review.
    Ortega Mateo A; de Artiñano AA
    Pharmacol Res; 1997 Nov; 36(5):339-51. PubMed ID: 9441724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endothelin receptor antagonists.
    Elliott JD; Ohlstein EH; Peishoff CE; Ellens HM; Lago MA
    Pharm Biotechnol; 1998; 11():113-29. PubMed ID: 9760678
    [No Abstract]   [Full Text] [Related]  

  • 53. Endothelin antagonists and heart failure.
    Hürlimann D; Enseleit F; Noll G; Lüscher TF; Ruschitzka F
    Curr Hypertens Rep; 2002 Feb; 4(1):85-92. PubMed ID: 11790297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure.
    Berger R; Stanek B; Hülsmann M; Frey B; Heher S; Pacher R; Neunteufl T
    Circulation; 2001 Feb; 103(7):981-6. PubMed ID: 11181473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
    Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
    Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
    Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
    Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.
    Gardiner SM; March JE; Kemp PA; Mullins JJ; Bennett T
    Br J Pharmacol; 1995 Oct; 116(4):2237-44. PubMed ID: 8564254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
    Kiowski W; Sütsch G; Hunziker P; Müller P; Kim J; Oechslin E; Schmitt R; Jones R; Bertel O
    Lancet; 1995 Sep; 346(8977):732-6. PubMed ID: 7658874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
    Kaluski E; Kobrin I; Zimlichman R; Marmor A; Krakov O; Milo O; Frey A; Kaplan S; Krakover R; Caspi A; Vered Z; Cotter G
    J Am Coll Cardiol; 2003 Jan; 41(2):204-10. PubMed ID: 12535809
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal failure in cirrhosis.
    Izzedine H; Baumelou A
    N Engl J Med; 2010 Jan; 362(1):80; author reply 80-1. PubMed ID: 20058337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.